Chemo and immunotherapy plus chest radiation for stage III lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial studies a treatment plan that combines chemotherapy, immunotherapy, and radiation to the chest for people with unresectable stage III non-small-cell lung cancer (NSCLC). It may help by delivering anti-cancer drugs while also shrinking tumors with targeted radiation, especially for people who are not able to have the standard “chemo and radiation at the same time.”
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage III non-small-cell lung cancer that cannot be removed with surgery.
- Your cancer has been confirmed under a microscope (by tissue or fluid sample).
- Your medical team decided you cannot do the usual combined (concurrent) chemo and radiation because of frailty or risk factors like age 70+ or limited activity level.
- You have enough heart/blood, liver, and kidney function for treatment.
- At least one visible chest tumor can be measured and can be treated with radiation.
- You have lung function strong enough for radiation (FEV1 and DLCO must be above their study cutoffs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving the immunotherapy drug durvalumab after chemoradiation and surgery helps people with stage 3 non-small cell lung cancer. You will receive standard chemoradiation, then have surgery, and then get durvalumab to see if it lowers the chance of the cancer coming back.
This trial tests a new combination of immunotherapy and chemotherapy before and after standard chemoradiation for patients with stage III lung cancer that cannot be surgically removed. The goal is to see if this approach improves outcomes compared to chemoradiation alone.
This study tests whether combining chemotherapy with immunotherapy before and after chemoradiation helps people with stage III lung cancer that can be removed by surgery. It might improve how well treatment works and reduce the chance of cancer coming back.
This trial tests whether combining radiation, an immunotherapy drug (toripalimab), and chemotherapy before surgery can help shrink tumors and improve outcomes in people with resectable stage II to III non-small cell lung cancer. It aims to see if this approach works better than standard chemotherapy alone.
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
This study tests a new combination of radiation therapy, an immunotherapy drug called tislelizumab, and chemotherapy for people with bulky stage III non-small cell lung cancer. The goal is to see if this approach can shrink tumors more effectively and improve outcomes.
Hear when a new Non-small Cell Lung Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.